Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment The FDA has granted Innovent's IBI3003 Fast Track Designation for treating relapsed multiple myeloma, enhancing development and approval speeds.

Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment #United_States #San_Francisco #Multiple_Myeloma #Innovent #IBI3003

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma Innovent Biologics presents initial findings from its first-in-human trial of the trispecific antibody IBI3003 for relapsed multiple myeloma at ASH 2025.

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003